China SXT Pharmaceuticals (SXTC) Payables (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Payables for 9 consecutive years, with $852823.0 the latest figure, recorded in Q1 2026.

• Quarterly Payables fell 54.16% year-over-year to $852823.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $852823.0 (down 54.16% YoY) and the FY2026 annual result came in at $852823.0, down 54.16% from the prior year.
• Payables retreated to $852823.0 in Q1 2026 per SXTC's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Payables for SXTC reached as high as $3.5 million in Q1 2022 and fell as low as $852823.0 in Q1 2026.
• A 5-year average of $1.8 million and a median of $1.6 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables tumbled 56.22% — and 2024, when it soared 78.93%.
• Year by year, Payables stood at $1.6 million in 2022, then declined by 15.34% to $1.3 million in 2023, then jumped by 78.93% to $2.4 million in 2024, then slumped by 36.28% to $1.5 million in 2025, then sank by 43.41% to $852823.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $852823.0, $1.5 million, and $1.9 million for Q1 2026, Q3 2025, and Q1 2025 respectively.